Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 97

1.

Pharmacodynamics of Tebipenem: New Options for Oral Treatment of Multidrug-Resistant Gram-Negative Infections.

McEntee L, Johnson A, Farrington N, Unsworth J, Dane A, Jain A, Cotroneo N, Critchley I, Melnick D, Parr T, Ambrose PG, Das S, Hope W.

Antimicrob Agents Chemother. 2019 Jul 25;63(8). pii: e00603-19. doi: 10.1128/AAC.00603-19. Print 2019 Aug.

PMID:
31109982
2.

Dalbavancin Population Pharmacokinetic Modeling and Target Attainment Analysis.

Carrothers TJ, Chittenden JT, Critchley I.

Clin Pharmacol Drug Dev. 2019 May 14. doi: 10.1002/cpdd.695. [Epub ahead of print]

PMID:
31087630
3.

Randomized Trial of Ceftazidime-Avibactam vs Meropenem for Treatment of Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia (REPROVE): Analyses per US FDA-Specified End Points.

Torres A, Rank D, Melnick D, Rekeda L, Chen X, Riccobene T, Critchley IA, Lakkis HD, Taylor D, Talley AK.

Open Forum Infect Dis. 2019 Apr 25;6(4):ofz149. doi: 10.1093/ofid/ofz149. eCollection 2019 Apr.

4.

Dose Selection and Validation for Ceftazidime-Avibactam in Adults with Complicated Intra-abdominal Infections, Complicated Urinary Tract Infections, and Nosocomial Pneumonia.

Das S, Li J, Riccobene T, Carrothers TJ, Newell P, Melnick D, Critchley IA, Stone GG, Nichols WW.

Antimicrob Agents Chemother. 2019 Mar 27;63(4). pii: e02187-18. doi: 10.1128/AAC.02187-18. Print 2019 Apr. Review.

5.

Microbiological Profile of Sarecycline, a Novel Targeted Spectrum Tetracycline for the Treatment of Acne Vulgaris.

Zhanel G, Critchley I, Lin LY, Alvandi N.

Antimicrob Agents Chemother. 2018 Dec 21;63(1). pii: e01297-18. doi: 10.1128/AAC.01297-18. Print 2019 Jan.

6.

Ceftazidime-Avibactam Susceptibility Breakpoints against Enterobacteriaceae and Pseudomonas aeruginosa.

Nichols WW, Stone GG, Newell P, Broadhurst H, Wardman A, MacPherson M, Yates K, Riccobene T, Critchley IA, Das S.

Antimicrob Agents Chemother. 2018 Oct 24;62(11). pii: e02590-17. doi: 10.1128/AAC.02590-17. Print 2018 Nov.

7.

Avibactam Pharmacokinetic/Pharmacodynamic Targets.

Nichols WW, Newell P, Critchley IA, Riccobene T, Das S.

Antimicrob Agents Chemother. 2018 May 25;62(6). pii: e02446-17. doi: 10.1128/AAC.02446-17. Print 2018 Jun. Review.

8.

Assessment of 30/20-Microgram Disk Content versus MIC Results for Ceftazidime-Avibactam Tested against Enterobacteriaceae and Pseudomonas aeruginosa.

Sader HS, Rhomberg PR, Huband MD, Critchley IA, Stone GG, Flamm RK, Jones RN.

J Clin Microbiol. 2018 May 25;56(6). pii: e01960-17. doi: 10.1128/JCM.01960-17. Print 2018 Jun.

9.

Fosfomycin and Comparator Activity Against Select Enterobacteriaceae, Pseudomonas, and Enterococcus Urinary Tract Infection Isolates from the United States in 2012.

Keepers TR, Gomez M, Celeri C, Krause KM, Biek D, Critchley I.

Infect Dis Ther. 2017 Jun;6(2):233-243. doi: 10.1007/s40121-017-0150-5. Epub 2017 Mar 11.

10.

New Antimicrobial Agents  …  but No Susceptibility Tests!

Ambler JE, Krause KM, Steenbergen JN, Scangarella-Oman NE, Miller LA, Bhagwat SS, Serio AW, Chesnel L, Mahoney NM, Motyl MR, Critchley IA, Iaconis JP, Stone GG, Alder J, Xerri L, McCurdy SP, van Veenhuyzen DF, Grossman T, Echols RM, Williams G, Bradford PA.

Clin Infect Dis. 2016 Dec 1;63(11):1530-1531. Epub 2016 Aug 31. No abstract available.

PMID:
27581762
11.

Evolution of Ceftaroline-Resistant Mrsa in a Child with Cystic Fibrosis Following Repeated Antibiotic Exposure.

Cannavino CR, Mendes RE, Sader HS, Farrell DJ, Critchley IA, Biek D, Le J, Skochko SM, Jones RN, Bradley JS.

Pediatr Infect Dis J. 2016 Jul;35(7):813-5. doi: 10.1097/INF.0000000000001171.

PMID:
27093165
12.

Effects of surgical management on multidirectional instability of the shoulder: a meta-analysis.

Chen D, Goldberg J, Herald J, Critchley I, Barmare A.

Knee Surg Sports Traumatol Arthrosc. 2016 Feb;24(2):630-9. doi: 10.1007/s00167-015-3901-4. Epub 2015 Dec 12.

PMID:
26658564
13.

Ceftazidime-avibactam for the treatment of complicated urinary tract infections and complicated intra-abdominal infections.

Mawal Y, Critchley IA, Riccobene TA, Talley AK.

Expert Rev Clin Pharmacol. 2015;8(6):691-707. doi: 10.1586/17512433.2015.1090874. Epub 2015 Sep 30. Review.

PMID:
26420166
14.

Accuracy of the Thermo Fisher Scientific (Sensititre™) dry-form broth microdilution MIC product when testing ceftaroline.

Jones RN, Holliday NM, Critchley IA.

Diagn Microbiol Infect Dis. 2015 Apr;81(4):280-2. doi: 10.1016/j.diagmicrobio.2014.12.010. Epub 2014 Dec 30.

PMID:
25623933
15.

Effect of In Vitro Testing Parameters on Ceftazidime-Avibactam Minimum Inhibitory Concentrations.

Keepers TR, Gomez M, Biek D, Critchley I, Krause KM.

Int Sch Res Notices. 2015 May 19;2015:489547. doi: 10.1155/2015/489547. eCollection 2015.

16.

Serotype distribution and antimicrobial susceptibility of USA Streptococcus pneumoniae isolates collected prior to and post introduction of 13-valent pneumococcal conjugate vaccine.

Mendes RE, Costello AJ, Jacobs MR, Biek D, Critchley IA, Jones RN.

Diagn Microbiol Infect Dis. 2014 Sep;80(1):19-25. doi: 10.1016/j.diagmicrobio.2014.05.020. Epub 2014 May 24.

PMID:
24974272
17.

Decreased ceftriaxone susceptibility in emerging (35B and 6C) and persisting (19A) Streptococcus pneumoniae serotypes in the United States, 2011-2012: ceftaroline remains active in vitro among β-lactam agents.

Mendes RE, Biek D, Critchley IA, Farrell DJ, Sader HS, Jones RN.

Antimicrob Agents Chemother. 2014 Aug;58(8):4923-7. doi: 10.1128/AAC.02976-14. Epub 2014 May 27.

18.

Pharmacokinetic-pharmacodynamic target attainment analyses to evaluate in vitro susceptibility test interpretive criteria for ceftaroline against Staphylococcus aureus and Streptococcus pneumoniae.

Van Wart SA, Ambrose PG, Rubino CM, Khariton T, Riccobene TA, Friedland HD, Critchley IA, Bhavnani SM.

Antimicrob Agents Chemother. 2014;58(2):885-91. doi: 10.1128/AAC.01680-13. Epub 2013 Nov 25.

19.

Review of para-articular soft tissue osteochondromas of the knee.

Zhang BX, Chew D, Critchley I.

ANZ J Surg. 2012 Dec;82(12):878-84. doi: 10.1111/j.1445-2197.2012.06206.x. Epub 2012 Sep 19. Review.

PMID:
22989085
20.

Panton-Valentine leukocidin is not the primary determinant of outcome for Staphylococcus aureus skin infections: evaluation from the CANVAS studies.

Tong A, Tong SY, Zhang Y, Lamlertthon S, Sharma-Kuinkel BK, Rude T, Ahn SH, Ruffin F, Llorens L, Tamarana G, Biek D, Critchley I, Fowler VG Jr.

PLoS One. 2012;7(5):e37212. doi: 10.1371/journal.pone.0037212. Epub 2012 May 18.

21.

Pharmacodynamics of β-lactamase inhibition by NXL104 in combination with ceftaroline: examining organisms with multiple types of β-lactamases.

Louie A, Castanheira M, Liu W, Grasso C, Jones RN, Williams G, Critchley I, Thye D, Brown D, Vanscoy B, Kulawy R, Drusano GL.

Antimicrob Agents Chemother. 2012 Jan;56(1):258-70. doi: 10.1128/AAC.05005-11. Epub 2011 Oct 24.

22.

Activity of ceftaroline and epidemiologic trends in Staphylococcus aureus isolates collected from 43 medical centers in the United States in 2009.

Richter SS, Heilmann KP, Dohrn CL, Riahi F, Costello AJ, Kroeger JS, Biek D, Critchley IA, Diekema DJ, Doern GV.

Antimicrob Agents Chemother. 2011 Sep;55(9):4154-60. doi: 10.1128/AAC.00315-11. Epub 2011 Jun 27.

23.

FOCUS 2: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia.

Low DE, File TM Jr, Eckburg PB, Talbot GH, David Friedland H, Lee J, Llorens L, Critchley IA, Thye DA; FOCUS 2 investigators.

J Antimicrob Chemother. 2011 Apr;66 Suppl 3:iii33-44. doi: 10.1093/jac/dkr097.

PMID:
21482568
24.

FOCUS 1: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia.

File TM Jr, Low DE, Eckburg PB, Talbot GH, Friedland HD, Lee J, Llorens L, Critchley IA, Thye DA; FOCUS 1 investigators.

J Antimicrob Chemother. 2011 Apr;66 Suppl 3:iii19-32. doi: 10.1093/jac/dkr096.

PMID:
21482566
25.

Review of ceftaroline fosamil microbiology: integrated FOCUS studies.

Critchley IA, Eckburg PB, Jandourek A, Biek D, Friedland HD, Thye DA.

J Antimicrob Chemother. 2011 Apr;66 Suppl 3:iii45-51. doi: 10.1093/jac/dkr098. Review.

PMID:
21482569
26.

Ceftaroline fosamil: a novel broad-spectrum cephalosporin with expanded anti-Gram-positive activity.

Biek D, Critchley IA, Riccobene TA, Thye DA.

J Antimicrob Chemother. 2010 Nov;65 Suppl 4:iv9-16. doi: 10.1093/jac/dkq251. Review.

PMID:
21115457
27.

Fatal clostridial necrotising myofasciitis (gas gangrene) following femoral nerve block.

White N, Ek ET, Critchley I.

ANZ J Surg. 2010 Dec;80(12):948-9. doi: 10.1111/j.1445-2197.2010.05562.x. No abstract available.

PMID:
21114743
28.

Integrated analysis of FOCUS 1 and FOCUS 2: randomized, doubled-blinded, multicenter phase 3 trials of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in patients with community-acquired pneumonia.

File TM Jr, Low DE, Eckburg PB, Talbot GH, Friedland HD, Lee J, Llorens L, Critchley I, Thye D.

Clin Infect Dis. 2010 Dec 15;51(12):1395-405. doi: 10.1086/657313. Epub 2010 Nov 10. Erratum in: Clin Infect Dis. 2011 Apr 1;52(7):967.

PMID:
21067350
29.

Integrated analysis of CANVAS 1 and 2: phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infection.

Corey GR, Wilcox M, Talbot GH, Friedland HD, Baculik T, Witherell GW, Critchley I, Das AF, Thye D.

Clin Infect Dis. 2010 Sep 15;51(6):641-50. doi: 10.1086/655827.

PMID:
20695801
30.

Activity of chequerboard combinations of ceftaroline and NXL104 versus beta-lactamase-producing Enterobacteriaceae.

Mushtaq S, Warner M, Williams G, Critchley I, Livermore DM.

J Antimicrob Chemother. 2010 Jul;65(7):1428-32. doi: 10.1093/jac/dkq161. Epub 2010 May 17.

PMID:
20478991
31.

Activity of ceftaroline against recent emerging serotypes of Streptococcus pneumoniae in the United States.

Jacobs MR, Good CE, Windau AR, Bajaksouzian S, Biek D, Critchley IA, Sader HS, Jones RN.

Antimicrob Agents Chemother. 2010 Jun;54(6):2716-9. doi: 10.1128/AAC.01797-09. Epub 2010 Mar 22.

32.

Pharmacokinetic-pharmacodynamic assessment of faropenem in a lethal murine Bacillus anthracis inhalation postexposure prophylaxis model.

Gill SC, Rubino CM, Bassett J, Miller L, Ambrose PG, Bhavnani SM, Beaudry A, Li J, Stone KC, Critchley I, Janjic N, Heine HS.

Antimicrob Agents Chemother. 2010 May;54(5):1678-83. doi: 10.1128/AAC.00737-08. Epub 2010 Feb 9.

33.

Spectrum of activity and mode of action of REP3123, a new antibiotic to treat Clostridium difficile infections.

Critchley IA, Green LS, Young CL, Bullard JM, Evans RJ, Price M, Jarvis TC, Guiles JW, Janjic N, Ochsner UA.

J Antimicrob Chemother. 2009 May;63(5):954-63. doi: 10.1093/jac/dkp041. Epub 2009 Mar 3.

PMID:
19258353
34.

Inhibitory effect of REP3123 on toxin and spore formation in Clostridium difficile, and in vivo efficacy in a hamster gastrointestinal infection model.

Ochsner UA, Bell SJ, O'Leary AL, Hoang T, Stone KC, Young CL, Critchley IA, Janjic N.

J Antimicrob Chemother. 2009 May;63(5):964-71. doi: 10.1093/jac/dkp042. Epub 2009 Feb 26.

PMID:
19251726
35.

Quinazolin-2-ylamino-quinazolin-4-ols as novel non-nucleoside inhibitors of bacterial DNA polymerase III.

Guiles J, Sun X, Critchley IA, Ochsner U, Tregay M, Stone K, Bertino J, Green L, Sabin R, Dean F, Dallmann HG, McHenry CS, Janjic N.

Bioorg Med Chem Lett. 2009 Feb 1;19(3):800-2. doi: 10.1016/j.bmcl.2008.12.038. Epub 2008 Dec 13.

PMID:
19109016
36.

New agents for Clostridium difficile-associated disease.

Guiles J, Critchley I, Sun X.

Expert Opin Investig Drugs. 2008 Nov;17(11):1671-83. doi: 10.1517/13543784.17.11.1671 . Review.

PMID:
18922104
37.

Recent advances in the preclinical evaluation of the topical antibacterial agent REP8839.

Critchley IA, Ochsner UA.

Curr Opin Chem Biol. 2008 Aug;12(4):409-17. doi: 10.1016/j.cbpa.2008.06.011. Epub 2008 Jul 11. Review.

PMID:
18620074
38.

Prevalence of serotype 19A Streptococcus pneumoniae among isolates from U.S. children in 2005-2006 and activity of faropenem.

Critchley IA, Jacobs MR, Brown SD, Traczewski MM, Tillotson GS, Janjic N.

Antimicrob Agents Chemother. 2008 Jul;52(7):2639-43. doi: 10.1128/AAC.00310-08. Epub 2008 Apr 28.

39.

Susceptibility of Staphylococcus aureus isolated from skin and wound infections in the United States 2005-07: laboratory-based surveillance study.

Tillotson GS, Draghi DC, Sahm DF, Tomfohrde KM, Del Fabro T, Critchley IA.

J Antimicrob Chemother. 2008 Jul;62(1):109-15. doi: 10.1093/jac/dkn149. Epub 2008 Apr 8.

PMID:
18397923
40.

National and regional assessment of antimicrobial resistance among community-acquired respiratory tract pathogens identified in a 2005-2006 U.S. Faropenem surveillance study.

Critchley IA, Brown SD, Traczewski MM, Tillotson GS, Janjic N.

Antimicrob Agents Chemother. 2007 Dec;51(12):4382-9. Epub 2007 Oct 1.

41.

Aminoacyl-tRNA synthetases: essential and still promising targets for new anti-infective agents.

Ochsner UA, Sun X, Jarvis T, Critchley I, Janjic N.

Expert Opin Investig Drugs. 2007 May;16(5):573-93. Review.

PMID:
17461733
42.

Activity of faropenem against middle ear fluid pathogens from children with acute otitis media in Costa Rica and Israel.

Stone KC, Dagan R, Arguedas A, Leibovitz E, Wang E, Echols RM, Janjic N, Critchley IA.

Antimicrob Agents Chemother. 2007 Jun;51(6):2230-5. Epub 2007 Mar 26.

43.

Safety of autologous drainage blood reinfusion following total knee arthroplasty prepared with hydrogen peroxide.

Kolt JD, Robin DA, Carr AM, Chew DK, Critchley IJ, Horton RW.

Knee. 2007 Jan;14(1):12-8. Epub 2006 Dec 4.

PMID:
17142045
44.

Activity of faropenem tested against Neisseria gonorrhoeae isolates including fluoroquinolone-resistant strains.

Jones RN, Critchley IA, Whittington WL, Janjic N, Pottumarthy S.

Diagn Microbiol Infect Dis. 2005 Dec;53(4):311-7. Epub 2005 Nov 2.

PMID:
16269221
45.

Mode of action and biochemical characterization of REP8839, a novel inhibitor of methionyl-tRNA synthetase.

Ochsner UA, Young CL, Stone KC, Dean FB, Janjic N, Critchley IA.

Antimicrob Agents Chemother. 2005 Oct;49(10):4253-62.

46.

Antibacterial activity of REP8839, a new antibiotic for topical use.

Critchley IA, Young CL, Stone KC, Ochsner UA, Guiles J, Tarasow T, Janjic N.

Antimicrob Agents Chemother. 2005 Oct;49(10):4247-52.

47.

Combustion exhaust measurements of nitric oxide with an ultraviolet diode-laser-based absorption sensor.

Anderson TN, Lucht RP, Barron-Jimenez R, Hanna SF, Caton JA, Walther T, Roy S, Brown MS, Gord JR, Critchley I, Flamand L.

Appl Opt. 2005 Mar 10;44(8):1491-502.

PMID:
15796251
48.

Development of a standardized susceptibility test for campylobacter with quality-control ranges for ciprofloxacin, doxycycline, erythromycin, gentamicin, and meropenem.

McDermott PF, Bodeis SM, Aarestrup FM, Brown S, Traczewski M, Fedorka-Cray P, Wallace M, Critchley IA, Thornsberry C, Graff S, Flamm R, Beyer J, Shortridge D, Piddock LJ, Ricci V, Johnson MM, Jones RN, Reller B, Mirrett S, Aldrobi J, Rennie R, Brosnikoff C, Turnbull L, Stein G, Schooley S, Hanson RA, Walker RD.

Microb Drug Resist. 2004 Summer;10(2):124-31.

PMID:
15256027
49.

Optimal use of antibiotic resistance surveillance systems.

Critchley IA, Karlowsky JA.

Clin Microbiol Infect. 2004 Jun;10(6):502-11. Review.

50.

Antibiotic susceptibility of isolates of Bacillus anthracis, a bacterial pathogen with the potential to be used in biowarfare.

Jones ME, Goguen J, Critchley IA, Draghi DC, Karlowsky JA, Sahm DF, Porschen R, Patra G, DelVecchio VG.

Clin Microbiol Infect. 2003 Sep;9(9):984-6.

Supplemental Content

Loading ...
Support Center